SCHEMBL1098003

SCHEMBL1098003

CCCCN(c1sc2ccccc2c1Cl)S(=O)(=O)c1ccc(N2CCOCC2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 1/20 0.41
MAPT P10636 5/20 0.41
CYP2C19 P33261 3/20 0.41
CYP2C9 P11712 2/20 0.41
GAA P10253 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
PKM P14618 1/20 0.40
TSHR P16473 1/20 0.40
ALDH1A1 P00352 5/20 0.39
ESR1 P03372 1/20 0.38
RAB9A P51151 2/20 0.38
KDM4E B2RXH2 2/20 0.38
CYP2C8 P10632 1/20 0.38
CYP2C18 P33260 1/20 0.38
NPC1 O15118 1/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
ATM Q13315 1/20 0.38
MAPK1 P28482 1/20 0.37
CNR2 P34972 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1098983 0.89 RORC (0.41) RORCMAPTCYP2C19CYP2C9GAA
SCHEMBL1098670 0.84 TDP1 (0.49) MAPTCYP2C19CYP2C9ESR1CYP2C8
SCHEMBL1099308 0.81 ESR1 (0.46) MAPTGAAESR1KMT2AMEN1
SCHEMBL27789367 0.80 ESR1 (0.42) MAPTCYP2C19CYP2C9SMN1; SMN2ALDH1A1
SCHEMBL1098547 0.79 LMNA (0.48) MAPTGAASMN1; SMN2TSHRALDH1A1
SCHEMBL1099932 0.79 ALOX5 (0.57) GAASMN1; SMN2ESR1RAB9AL3MBTL1
SCHEMBL1099579 0.79 RORC (0.44) RORCMAPTCYP2C19CYP2C9PKM
SCHEMBL1098475 0.78 TRPM8 (0.43) RORCMAPTGAASMN1; SMN2PKM
SCHEMBL1100358 0.77 TRPM8 (0.41) RORCMAPTGAAPKMTSHR
SCHEMBL1098982 0.76 SMN1; SMN2 (0.37) RORCMAPTGAASMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 RORC 3514/4885MAPT 3324/4885CYP2C19 3025/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 RORC 3514/4885MAPT 3324/4885CYP2C19 3025/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 RORC 3514/4885MAPT 3324/4885CYP2C19 3025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.